Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects

Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...

Full description

Saved in:

Bibliographic Details
Published in	Antimicrobial Agents and Chemotherapy Vol. 47; no. 6; pp. 1929 - 1935
Main Authors	DiCenzo, Robert, Forrest, Alan, Squires, Kathleen E., Hammer, Scott M., Fischl, Margaret A., Wu, Hulin, Cha, Raymond, Morse, Gene D.
Format	Journal Article
Language	English
Published	Washington, DC American Society for Microbiology 01.06.2003
Subjects	Administration, Oral Adult Anti-HIV Agents Anti-HIV Agents - administration & dosage Anti-HIV Agents - blood Anti-HIV Agents - pharmacokinetics Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents Benzoxazines Biological and medical sciences Dideoxynucleosides Dideoxynucleosides - administration & dosage Dideoxynucleosides - blood Dideoxynucleosides - pharmacokinetics Drug Administration Schedule Drug Interactions Drug Therapy, Combination Female HIV Infections HIV Infections - drug therapy HIV Infections - metabolism HIV Infections - virology HIV-1 Humans Indinavir Indinavir - administration & dosage Indinavir - blood Indinavir - pharmacokinetics Male Medical sciences Oxazines Oxazines - administration & dosage Oxazines - blood Oxazines - pharmacokinetics Pharmacology. Drug treatments RNA, Viral - blood Human Immunopathology Drug combination Acetylenic compound Oral administration AIDS Immune deficiency Efavirenz Infection Multiple dose In vivo Viral disease Reverse transcriptase inhibitor Abacavir Antiviral Drug interaction Nucleosidic analog Pharmacokinetics Indinavir Protease inhibitor
Online Access	Get full text

Cover

Loading…

Abstract	Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC
AbstractList	Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, efavirenz, and abacavir in human immunodeficiency virus-infected subjects who received indinavir at 1,000 mg every 8 h (q8h) and efavirenz at 600 mg q24h or indinavir at 1,200 mg and efavirenz at 300 mg q12h with or without abacavir 300 at mg q12h. Thirty-six subjects participated. The median minimum concentration in plasma (C(min)) for indinavir administered at 1,200 mg q12h was 88.1 nM (interquartile range [IR], 61.7 to 116.5 nM), whereas the median C(min) for indinavir administered at 1,000 mg q8h was 139.3 nM (IR, 68.8 to 308.7 nM) (P = 0.19). Compared to the minimum C(min) range for wild-type virus (80 to 120 ng/ml) estimated by the AACTG Adult Pharmacology Committee, the C(min) for indinavir administered at 1,200 mg q12h (54 ng/ml) is inadequate. The apparent oral clearance (CL/F) (P = 0.28), apparent volume of distribution at steady state (V(ss)/F) (P = 0.25), and half-life (t(1/2)) (P = 0.80) of indinavir did not differ between regimens. The levels of efavirenz exposure were similar between regimens. For efavirenz administered at 600 mg q24h and 300 mg q12h, the median maximum concentrations in plasma (C(max)s) were 8,968 nM (IR, 5,784 to 11,768 nM) and 8,317 nM (6,587 to 10,239 nM), respectively (P = 0.66), and the C(min)s were 4,289 nM (IR, 2,462 to 5,904 nM) and 4,757 nM (IR, 3,088 to 6,644 nM), respectively (P = 0.29). Efavirenz pharmacokinetic parameters such as CL/F (P = 0.62), V(ss)/F (P = 0.33), and t(1/2) (P = 0.37) were similar regardless of the dosing regimen. The median C(max), C(min), CL/F, V(ss)/F, and t(1/2) for abacavir were 6,852 nM (IR, 5,702 to 7,532), 21.0 nM (IR, 21.0 to 87.5), 43.7 liters/h (IR, 37.9 to 55.2), 153.9 liters (IR, 79.6 to 164.4), and 2.0 h (IR, 1.8 to 2.8), respectively. In summary, when indinavir was given with efavirenz, the trough concentration of indinavir after administration of 1,200 mg q12h was inadequate. Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h. Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, efavirenz, and abacavir in human immunodeficiency virus-infected subjects who received indinavir at 1,000 mg every 8 h (q8h) and efavirenz at 600 mg q24h or indinavir at 1,200 mg and efavirenz at 300 mg q12h with or without abacavir 300 at mg q12h. Thirty-six subjects participated. The median minimum concentration in plasma ( C min ) for indinavir administered at 1,200 mg q12h was 88.1 nM (interquartile range [IR], 61.7 to 116.5 nM), whereas the median C min for indinavir administered at 1,000 mg q8h was 139.3 nM (IR, 68.8 to 308.7 nM) ( P = 0.19). Compared to the minimum C min range for wild-type virus (80 to 120 ng/ml) estimated by the AACTG Adult Pharmacology Committee, the C min for indinavir administered at 1,200 mg q12h (54 ng/ml) is inadequate. The apparent oral clearance (CL/F) ( P = 0.28), apparent volume of distribution at steady state ( V ss /F) ( P = 0.25), and half-life ( t 1/2 ) ( P = 0.80) of indinavir did not differ between regimens. The levels of efavirenz exposure were similar between regimens. For efavirenz administered at 600 mg q24h and 300 mg q12h, the median maximum concentrations in plasma ( C max s) were 8,968 nM (IR, 5,784 to 11,768 nM) and 8,317 nM (6,587 to 10,239 nM), respectively ( P = 0.66), and the C min s were 4,289 nM (IR, 2,462 to 5,904 nM) and 4,757 nM (IR, 3,088 to 6,644 nM), respectively ( P = 0.29). Efavirenz pharmacokinetic parameters such as CL/F ( P = 0.62), V ss /F ( P = 0.33), and t 1/2 ( P = 0.37) were similar regardless of the dosing regimen. The median C max , C min , CL/F, V ss / F , and t 1/2 for abacavir were 6,852 nM (IR, 5,702 to 7,532), 21.0 nM (IR, 21.0 to 87.5), 43.7 liters/h (IR, 37.9 to 55.2), 153.9 liters (IR, 79.6 to 164.4), and 2.0 h (IR, 1.8 to 2.8), respectively. In summary, when indinavir was given with efavirenz, the trough concentration of indinavir after administration of 1,200 mg q12h was inadequate. Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h. Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, efavirenz, and abacavir in human immunodeficiency virus-infected subjects who received indinavir at 1,000 mg every 8 h (q8h) and efavirenz at 600 mg q24h or indinavir at 1,200 mg and efavirenz at 300 mg q12h with or without abacavir 300 at mg q12h. Thirty-six subjects participated. The median minimum concentration in plasma (Cmin) for indinavir administered at 1,200 mg q12h was 88.1 nM (interquartile range [IR], 61.7 to 116.5 nM), whereas the median Cmin for indinavir administered at 1,000 mg q8h was 139.3 nM (IR, 68.8 to 308.7 nM) (P = 0.19). Compared to the minimum Cmin range for wild-type virus (80 to 120 ng/ml) estimated by the AACTG Adult Pharmacology Committee, the Cmin for indinavir administered at 1,200 mg q12h (54 ng/ml) is inadequate. The apparent oral clearance (CL/F) (P = 0.28), apparent volume of distribution at steady state (Vss/F) (P = 0.25), and half-life (t1/2) (P = 0.80) of indinavir did not differ between regimens. The levels of efavirenz exposure were similar between regimens. For efavirenz administered at 600 mg q24h and 300 mg q12h, the median maximum concentrations in plasma (Cmaxs) were 8,968 nM (IR, 5,784 to 11,768 nM) and 8,317 nM (6,587 to 10,239 nM), respectively (P = 0.66), and the Cmins were 4,289 nM (IR, 2,462 to 5,904 nM) and 4,757 nM (IR, 3,088 to 6,644 nM), respectively (P = 0.29). Efavirenz pharmacokinetic parameters such as CL/F (P = 0.62), Vss/F (P = 0.33), and t1/2 (P = 0.37) were similar regardless of the dosing regimen. The median Cmax, Cmin, CL/F, Vss/F, and t1/2 for abacavir were 6,852 nM (IR, 5,702 to 7,532), 21.0 nM (IR, 21.0 to 87.5), 43.7 liters/h (IR, 37.9 to 55.2), 153.9 liters (IR, 79.6 to 164.4), and 2.0 h (IR, 1.8 to 2.8), respectively. In summary, when indinavir was given with efavirenz, the trough concentration of indinavir after administration of 1,200 mg q12h was inadequate. Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h. Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, efavirenz, and abacavir in human immunodeficiency virus-infected subjects who received indinavir at 1,000 mg every 8 h (q8h) and efavirenz at 600 mg q24h or indinavir at 1,200 mg and efavirenz at 300 mg q12h with or without abacavir 300 at mg q12h. Thirty-six subjects participated. The median minimum concentration in plasma (C(min)) for indinavir administered at 1,200 mg q12h was 88.1 nM (interquartile range [IR], 61.7 to 116.5 nM), whereas the median C(min) for indinavir administered at 1,000 mg q8h was 139.3 nM (IR, 68.8 to 308.7 nM) (P = 0.19). Compared to the minimum C(min) range for wild-type virus (80 to 120 ng/ml) estimated by the AACTG Adult Pharmacology Committee, the C(min) for indinavir administered at 1,200 mg q12h (54 ng/ml) is inadequate. The apparent oral clearance (CL/F) (P = 0.28), apparent volume of distribution at steady state (V(ss)/F) (P = 0.25), and half-life (t(1/2)) (P = 0.80) of indinavir did not differ between regimens. The levels of efavirenz exposure were similar between regimens. For efavirenz administered at 600 mg q24h and 300 mg q12h, the median maximum concentrations in plasma (C(max)s) were 8,968 nM (IR, 5,784 to 11,768 nM) and 8,317 nM (6,587 to 10,239 nM), respectively (P = 0.66), and the C(min)s were 4,289 nM (IR, 2,462 to 5,904 nM) and 4,757 nM (IR, 3,088 to 6,644 nM), respectively (P = 0.29). Efavirenz pharmacokinetic parameters such as CL/F (P = 0.62), V(ss)/F (P = 0.33), and t(1/2) (P = 0.37) were similar regardless of the dosing regimen. The median C(max), C(min), CL/F, V(ss)/F, and t(1/2) for abacavir were 6,852 nM (IR, 5,702 to 7,532), 21.0 nM (IR, 21.0 to 87.5), 43.7 liters/h (IR, 37.9 to 55.2), 153.9 liters (IR, 79.6 to 164.4), and 2.0 h (IR, 1.8 to 2.8), respectively. In summary, when indinavir was given with efavirenz, the trough concentration of indinavir after administration of 1,200 mg q12h was inadequate. Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h.Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, efavirenz, and abacavir in human immunodeficiency virus-infected subjects who received indinavir at 1,000 mg every 8 h (q8h) and efavirenz at 600 mg q24h or indinavir at 1,200 mg and efavirenz at 300 mg q12h with or without abacavir 300 at mg q12h. Thirty-six subjects participated. The median minimum concentration in plasma (C(min)) for indinavir administered at 1,200 mg q12h was 88.1 nM (interquartile range [IR], 61.7 to 116.5 nM), whereas the median C(min) for indinavir administered at 1,000 mg q8h was 139.3 nM (IR, 68.8 to 308.7 nM) (P = 0.19). Compared to the minimum C(min) range for wild-type virus (80 to 120 ng/ml) estimated by the AACTG Adult Pharmacology Committee, the C(min) for indinavir administered at 1,200 mg q12h (54 ng/ml) is inadequate. The apparent oral clearance (CL/F) (P = 0.28), apparent volume of distribution at steady state (V(ss)/F) (P = 0.25), and half-life (t(1/2)) (P = 0.80) of indinavir did not differ between regimens. The levels of efavirenz exposure were similar between regimens. For efavirenz administered at 600 mg q24h and 300 mg q12h, the median maximum concentrations in plasma (C(max)s) were 8,968 nM (IR, 5,784 to 11,768 nM) and 8,317 nM (6,587 to 10,239 nM), respectively (P = 0.66), and the C(min)s were 4,289 nM (IR, 2,462 to 5,904 nM) and 4,757 nM (IR, 3,088 to 6,644 nM), respectively (P = 0.29). Efavirenz pharmacokinetic parameters such as CL/F (P = 0.62), V(ss)/F (P = 0.33), and t(1/2) (P = 0.37) were similar regardless of the dosing regimen. The median C(max), C(min), CL/F, V(ss)/F, and t(1/2) for abacavir were 6,852 nM (IR, 5,702 to 7,532), 21.0 nM (IR, 21.0 to 87.5), 43.7 liters/h (IR, 37.9 to 55.2), 153.9 liters (IR, 79.6 to 164.4), and 2.0 h (IR, 1.8 to 2.8), respectively. In summary, when indinavir was given with efavirenz, the trough concentration of indinavir after administration of 1,200 mg q12h was inadequate. Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h. Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, e. .a.i.human immunodeficiency virus-infected subjects who received indinavir at 1,000 mg every 8 h (q8h) and efavirenz at 600 mg q24h or indinavir at 1,200 mg and efavirenz at 300 mg q12h with or without abacavir 300 at mg q12h. Thirty-six subjects participated. The median minimum concentration in plasma (C sub(min)) for indinavir administered at 1,200 mg q12h was 88.1 nM (interquartile range (IR), 61.7 to 116.5 nM), whereas the median C sub(min) for indinavir administered at 1,000 mg q8h was 139.3 nM (IR, 68.8 to 308.7 nM) (P = 0.19). Compared to the minimum C sub(min) range for wild-type virus (80 to 120 ng/ml) estimated by the AACTG Adult Pharmacology Committee, the C sub(min) for indinavir administered at 1,200 mg q12h (54 ng/ml) is inadequate. The apparent oral clearance (CL/F) (P = 0.28), apparent volume of distribution at steady state (V sub(ss)/F) (P = 0.25), and half-life (t sub(1/2)) (P = 0.80) of indinavir did not differ between regimens. The levels of efavirenz exposure were similar between regimens. For efavirenz administered at 600 mg q24h and 300 mg q12h, the median maximum concentrations in plasma (C sub(max)s) were 8,968 nM (IR, 5,784 to 11,768 nM) and 8,317 nM (6,587 to 10,239 nM), respectively (P = 0.66), and the C sub(min)s were 4,289 nM (IR, 2,462 to 5,904 nM) and 4,757 nM (IR, 3,088 to 6,644 nM), respectively (P = 0.29). Efavirenz pharmacokinetic parameters such as CL/F (P = 0.62), V sub(ss)/F (P = 0.33), and t sub(1/2) (P = 0.37) were similar regardless of the dosing regimen. The median C sub(max), C sub(min), CL/F, V sub(ss)/F, and t sub(1/2) for abacavir were 6,852 nM (IR, 5,702 to 7,532), 21.0 nM (IR, 21.0 to 87.5), 43.7 liters/h (IR, 37.9 to 55.2), 153.9 liters (IR, 79.6 to 164.4), and 2.0 h (IR, 1.8 to 2.8), respectively. In summary, when indinavir was given with efavirenz, the trough concentration of indinavir after administration of 1,200 mg q12h was inadequate. Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h.
Author	Margaret A. Fischl Gene D. Morse Scott M. Hammer Alan Forrest The Adult AIDS Clinical Trials Group Protocol 368/886 Study Team Robert DiCenzo Kathleen E. Squires Hulin Wu Raymond Cha
AuthorAffiliation	University at Buffalo, Buffalo, New York, 1 University of Southern California, Los Angeles, California, 2 Columbia University, New York, New York, 6 University of Miami, Miami, Florida, 4 Harvard University, Boston, Massachusetts, 3 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 5
AuthorAffiliation_xml	– name: University at Buffalo, Buffalo, New York, 1 University of Southern California, Los Angeles, California, 2 Columbia University, New York, New York, 6 University of Miami, Miami, Florida, 4 Harvard University, Boston, Massachusetts, 3 National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 5
Author_xml	– sequence: 1 givenname: Robert surname: DiCenzo fullname: DiCenzo, Robert organization: University at Buffalo, Buffalo, New York – sequence: 2 givenname: Alan surname: Forrest fullname: Forrest, Alan organization: University at Buffalo, Buffalo, New York – sequence: 3 givenname: Kathleen E. surname: Squires fullname: Squires, Kathleen E. organization: University of Southern California, Los Angeles, California – sequence: 4 givenname: Scott M. surname: Hammer fullname: Hammer, Scott M. organization: Harvard University, Boston, Massachusetts – sequence: 5 givenname: Margaret A. surname: Fischl fullname: Fischl, Margaret A. organization: University of Miami, Miami, Florida – sequence: 6 givenname: Hulin surname: Wu fullname: Wu, Hulin organization: National Institute of Allergy and Infectious Diseases, Bethesda, Maryland – sequence: 7 givenname: Raymond surname: Cha fullname: Cha, Raymond organization: Columbia University, New York, New York – sequence: 8 givenname: Gene D. surname: Morse fullname: Morse, Gene D. organization: University at Buffalo, Buffalo, New York
BackLink	http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14834855$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/12760869$$D View this record in MEDLINE/PubMed
BookMark	eNqNkstu1DAUhi1URKeFV4CwgFUz2LFjO4suRqNCR6oEEpetdcaXjofEKXZS1D59Hc3AAJuyOr58v8_l9wk6Cn2wCL0ieE5IJd8tFss5E3M-J03VlKSh9bzCmD5BM4IbWfK64UdohjHnJZOYHaOTlLY47-sGP0PHpBIcS97MkF0F4wPc-nhWXLgp2nB_VkAwxWINejooPm0gdqD77z7YwetU-FBcjh2EYtV1Y-iNdV57G_Rd8c3HMZWr4KwerCk-j-ttXqXn6KmDNtkX-3iKvr6_-LK8LK8-flgtF1cl1IwNpcV4LQxwwR2hFdO4to6AoNIRZmxFDbVrySl23FijKWZSCDC1AWYtYU7QU3S-e_dmXHcZsWGI0Kqb6DuId6oHr_6-CX6jrvtbRepaEpn1b_f62P8YbRpU55O2bQvB9mNSguakVUMeBUmuTOCqziDbgZC6Sm37MYY8AEWwmnxU2UfFhOJq8lFNPqrJxyx7-Wcjvzv4ZVwG3uwBSBpaFyFonw4ck5TJesovdpyOfUrRugPyaAnn_yi1H2Dw_TQ53_6H_vVOv_HXm5_5X6k8AgWgDzR9ALrT2T4
CODEN	AACHAX
CitedBy_id	crossref_primary_10_1097_01_aids_0000210609_52836_d1 crossref_primary_10_1002_jps_21411 crossref_primary_10_2165_00003088_200847060_00001 crossref_primary_10_2165_00003088_200544120_00005 crossref_primary_10_1097_00126334_200312010_00005 crossref_primary_10_1208_s12249_013_0016_4 crossref_primary_10_1007_s12325_010_0006_9 crossref_primary_10_1310_hct1105_312 crossref_primary_10_1128_AAC_48_11_4328_4331_2004 crossref_primary_10_1517_14656566_8_3_371 crossref_primary_10_1128_AAC_48_9_3226_3232_2004 crossref_primary_10_1002_bdd_597 crossref_primary_10_1111_j_1365_2125_2005_02436_x crossref_primary_10_1128_AAC_03469_14 crossref_primary_10_1124_jpet_117_243139
Cites_doi	10.1128/AAC.44.8.2052-2060.2000 10.1128/AAC.43.3.609 10.1128/AAC.45.1.30-37.2001 10.1086/314703 10.1097/00002030-200101050-00011 10.1067/mcp.2002.121424 10.2165/00003088-200140120-00002 10.1086/515317 10.1159/000046045 10.1086/313852 10.1128/AAC.43.3.603 10.1097/00002030-200007070-00005 10.1097/00002030-200009080-00013 10.2165/00003088-199937060-00004 10.1046/j.1365-2125.1999.00071.x 10.1038/86882 10.1016/0010-468X(79)90025-4 10.1128/AAC.43.12.2855 10.1128/AAC.43.7.1708 10.1128/AAC.44.8.2061-2067.2000 10.1097/00002030-200203080-00006 10.1086/318083 10.1089/08892220260190290 10.1073/pnas.95.22.13176
ContentType	Journal Article
Copyright	2003 INIST-CNRS Copyright © 2003 American Society for Microbiology Copyright © 2003, American Society for Microbiology 2003
Copyright_xml	– notice: 2003 INIST-CNRS – notice: Copyright © 2003 American Society for Microbiology – notice: Copyright © 2003, American Society for Microbiology 2003
CorporateAuthor	Adult AIDS Clinical Trials Group Protocol 368/886 Study Team
CorporateAuthor_xml	– name: Adult AIDS Clinical Trials Group Protocol 368/886 Study Team
DBID	AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 5PM
DOI	10.1128/AAC.47.6.1929-1935.2003
DatabaseName	CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Virology and AIDS Abstracts MEDLINE - Academic
DatabaseTitleList	MEDLINE CrossRef MEDLINE - Academic AIDS and Cancer Research Abstracts
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine Pharmacy, Therapeutics, & Pharmacology Biology
EISSN	1098-6596
EndPage	1935
ExternalDocumentID	PMC155818 0577 12760869 14834855 10_1128_AAC_47_6_1929_1935_2003 aac_47_6_1929
Genre	Clinical Trial, Phase II Research Support, U.S. Gov't, P.H.S Clinical Trial Randomized Controlled Trial Journal Article
GrantInformation_xml	– fundername: NCI NIH HHS grantid: 200PC006
GroupedDBID	--- .55 .GJ 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAGFI AAYXX ACGFO ADBBV AENEX AGNAY AGVNZ AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZGI ZXP ~A~ IQODW CGR CUY CVF ECM EIF NPM RHF - 08R 0R 55 A AAPBV ABFLS ADACO ADBIT AFMIJ BXI GJ HZ ZA5 7U9 H94 7X8 5PM
ID	FETCH-LOGICAL-a544t-e00b7da676f1324c05ef1a738f14de23d3eb8630f6dedc304877ad5da4ee14f73
ISSN	0066-4804
IngestDate	Thu Aug 21 14:37:20 EDT 2025 Fri Jul 11 08:03:32 EDT 2025 Fri Jul 11 07:06:50 EDT 2025 Tue Dec 28 13:58:52 EST 2021 Sat Sep 28 08:36:55 EDT 2024 Mon Jul 21 09:15:03 EDT 2025 Tue Jul 01 02:00:00 EDT 2025 Thu Apr 24 23:09:19 EDT 2025 Wed May 18 15:27:05 EDT 2016
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	Human Immunopathology Drug combination Acetylenic compound Oral administration AIDS Immune deficiency Efavirenz Infection Multiple dose In vivo Viral disease Reverse transcriptase inhibitor Abacavir Antiviral Drug interaction Nucleosidic analog Pharmacokinetics Indinavir Protease inhibitor
Language	English
License	CC BY 4.0
LinkModel	OpenURL
MergedId	FETCHMERGED-LOGICAL-a544t-e00b7da676f1324c05ef1a738f14de23d3eb8630f6dedc304877ad5da4ee14f73
Notes	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 Corresponding author. Mailing address: AACTG Pharmacology Support Laboratory, School of Pharmacy and Pharmaceutical Sciences, 317 Hochstetter Hall, University at Buffalo, Amherst, NY 14260. Phone: (716) 645-2828. Fax: (716) 645-2886. E-mail: emorse@acsu.buffalo.edu.
OpenAccessLink	http://doi.org/10.1128/AAC.47.6.1929-1935.2003
PMID	12760869
PQID	18777025
PQPubID	23462
PageCount	7
ParticipantIDs	crossref_primary_10_1128_AAC_47_6_1929_1935_2003 pubmed_primary_12760869 pubmedcentral_primary_oai_pubmedcentral_nih_gov_155818 asm2_journals_10_1128_AAC_47_6_1929_1935_2003 proquest_miscellaneous_18777025 crossref_citationtrail_10_1128_AAC_47_6_1929_1935_2003 pascalfrancis_primary_14834855 highwire_asm_aac_47_6_1929 proquest_miscellaneous_73304291
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2003-06-01
PublicationDateYYYYMMDD	2003-06-01
PublicationDate_xml	– month: 06 year: 2003 text: 2003-06-01 day: 01
PublicationDecade	2000
PublicationPlace	Washington, DC
PublicationPlace_xml	– name: Washington, DC – name: United States
PublicationTitle	Antimicrobial Agents and Chemotherapy
PublicationTitleAbbrev	AAC
PublicationTitleAlternate	Antimicrob Agents Chemother
PublicationYear	2003
Publisher	American Society for Microbiology
Publisher_xml	– name: American Society for Microbiology
References	e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_20_2 e_1_3_2_21_2 e_1_3_2_23_2 e_1_3_2_24_2 e_1_3_2_25_2 (e_1_3_2_8_2) 1999; 37 (e_1_3_2_5_2) 2000; 21 e_1_3_2_9_2 e_1_3_2_15_2 (e_1_3_2_10_2) 1998; 95 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 (e_1_3_2_12_2) 2000; 14 e_1_3_2_19_2 (e_1_3_2_16_2) 2001; 89 (e_1_3_2_3_2); 18 e_1_3_2_11_2 e_1_3_2_4_2 e_1_3_2_13_2 e_1_3_2_2_2 (e_1_3_2_22_2) 1999; 179 (e_1_3_2_14_2) 1998; 177
References_xml	– ident: e_1_3_2_27_2 doi: 10.1128/AAC.44.8.2052-2060.2000 – ident: e_1_3_2_15_2 doi: 10.1128/AAC.43.3.609 – ident: e_1_3_2_23_2 doi: 10.1128/AAC.45.1.30-37.2001 – volume: 179 start-page: 1116 year: 1999 ident: e_1_3_2_22_2 publication-title: J. Infect. Dis. doi: 10.1086/314703 – ident: e_1_3_2_19_2 doi: 10.1097/00002030-200101050-00011 – ident: e_1_3_2_2_2 doi: 10.1067/mcp.2002.121424 – ident: e_1_3_2_24_2 doi: 10.2165/00003088-200140120-00002 – volume: 177 start-page: 1514 year: 1998 ident: e_1_3_2_14_2 publication-title: J. Infect. Dis. doi: 10.1086/515317 – volume: 89 start-page: 62 year: 2001 ident: e_1_3_2_16_2 publication-title: Nephron doi: 10.1159/000046045 – ident: e_1_3_2_4_2 doi: 10.1086/313852 – ident: e_1_3_2_7_2 – ident: e_1_3_2_18_2 doi: 10.1128/AAC.43.3.603 – ident: e_1_3_2_9_2 doi: 10.1097/00002030-200007070-00005 – volume: 14 start-page: 1973 year: 2000 ident: e_1_3_2_12_2 publication-title: AIDS doi: 10.1097/00002030-200009080-00013 – volume: 37 start-page: 485 year: 1999 ident: e_1_3_2_8_2 publication-title: Clin. Pharmacokinet. doi: 10.2165/00003088-199937060-00004 – ident: e_1_3_2_25_2 doi: 10.1046/j.1365-2125.1999.00071.x – ident: e_1_3_2_17_2 doi: 10.1038/86882 – volume: 21 start-page: 424 year: 2000 ident: e_1_3_2_5_2 publication-title: Pharmacotherapy – ident: e_1_3_2_6_2 doi: 10.1016/0010-468X(79)90025-4 – ident: e_1_3_2_20_2 doi: 10.1128/AAC.43.12.2855 – ident: e_1_3_2_26_2 doi: 10.1128/AAC.43.7.1708 – ident: e_1_3_2_21_2 doi: 10.1128/AAC.44.8.2061-2067.2000 – ident: e_1_3_2_11_2 doi: 10.1097/00002030-200203080-00006 – ident: e_1_3_2_13_2 doi: 10.1086/318083 – volume: 18 start-page: 825 ident: e_1_3_2_3_2 publication-title: Hum. Retrovir. doi: 10.1089/08892220260190290 – volume: 95 start-page: 13176 year: 1998 ident: e_1_3_2_10_2 publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.95.22.13176
SSID	ssj0006590
Score	1.8154587
Snippet	Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, efavirenz, and abacavir in human immunodeficiency virus-infected... Adult AIDS Clinical Trials Group (AACTG) Protocol 886 examined the dispositions of indinavir, e. .a.i.human immunodeficiency virus-infected subjects who...
SourceID	pubmedcentral proquest asm2 pubmed pascalfrancis crossref highwire
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	1929
SubjectTerms	Administration, Oral Adult Anti-HIV Agents Anti-HIV Agents - administration & dosage Anti-HIV Agents - blood Anti-HIV Agents - pharmacokinetics Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral Agents Benzoxazines Biological and medical sciences Dideoxynucleosides Dideoxynucleosides - administration & dosage Dideoxynucleosides - blood Dideoxynucleosides - pharmacokinetics Drug Administration Schedule Drug Interactions Drug Therapy, Combination Female HIV Infections HIV Infections - drug therapy HIV Infections - metabolism HIV Infections - virology HIV-1 Humans Indinavir Indinavir - administration & dosage Indinavir - blood Indinavir - pharmacokinetics Male Medical sciences Oxazines Oxazines - administration & dosage Oxazines - blood Oxazines - pharmacokinetics Pharmacology. Drug treatments RNA, Viral - blood
Title	Indinavir, Efavirenz, and Abacavir Pharmacokinetics in Human Immunodeficiency Virus-Infected Subjects
URI	http://aac.asm.org/content/47/6/1929.abstract https://www.ncbi.nlm.nih.gov/pubmed/12760869 https://journals.asm.org/doi/10.1128/AAC.47.6.1929-1935.2003 https://www.proquest.com/docview/18777025 https://www.proquest.com/docview/73304291 https://pubmed.ncbi.nlm.nih.gov/PMC155818
Volume	47
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIhAXBOXVBRYf0F5oSuM4TnqsCmhBKlqJrrS3yEmc3QiaVqRF6v4EfjXjV9xUrRa4RFFiW07miz0zmfkGobcBKeI4LaiX-Wnk0YJkXiyI8DgPMz_jeVyoOmTTr-zsgn65DC87nd9bUUvrVTrIbvbmlfyPVOEayFVmyf6DZJtB4QKcg3zhCBKG41_J-LNMSeG_Sl3_pJBnorqxAZk85Zm89G5p6Km_g0apWJnLytTmK2V2yCIXkkZC5WBC83Xt6QgtUEXrdSr9NPW2CjuuVuW8VPxNkmfgSqXIqey4azE3-VyNn_5DOYEZLVwMt9v1VFUQnWPjEPpNBibrlcvGebhcCe1lV_5axSgxbbksAhdaZZdhxjwa67rDdhnWxJsGbttrKuigo_2LPZEJDOPxZECjARvIdh7oo6Fied3uAVJbzhUGfBIxMOJGbvdrYhLtrTvoLgGTg1jPj9nVWaj9dXbqJlYQ5vD-wAwkH60ZE_Z7Xs9JW_exfNQyHJfX8EUWupTKPltnN2R3SweaPUIPjfGCxxqJj1FHVF10T5cz3XTR_akJ1Oii03ONuU0fz1yGX93Hp_jckaVvniDRYLiPGwT3MeAJW_ziXfzissIKv3gXv7iNX2zx-xRdfPo4m5x5pvSHx0NKV54YDtMo5yxihQ8qfzYMReHzKIgLn-aCBHkg0pgFw4Ll8E4C2IaiiOdhzqkQPi2i4Bk6qhaVeIFwEJE0A6MFJMdpQEkK0iNM5LAOkTQIWQ95UjaJ-a7rRJnFJE5ArAmNEpZIsSZSrLJma9BDzAoxyQyPvizn8uP2jsOm41JTydze5diiJIFJJpxnrlkPnbRw4waVPwjiMOyhNxZICWwa8k8gr8RiDY8oWUDB2jncIlJ-zpHfQ8818NzoBtPwHlqQbBpIwvr2naq8VsT1YLuAfXB8cMiX6IFbLl6ho9XPtXgNOv8qPVEf4x8Rf_2h
linkProvider	National Library of Medicine
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Indinavir%2C+efavirenz%2C+and+abacavir+pharmacokinetics+in+human+immunodeficiency+virus-infected+subjects&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=DiCenzo%2C+Robert&rft.au=Forrest%2C+Alan&rft.au=Squires%2C+Kathleen+E&rft.au=Hammer%2C+Scott+M&rft.date=2003-06-01&rft.issn=0066-4804&rft.volume=47&rft.issue=6&rft.spage=1929&rft_id=info:doi/10.1128%2FAAC.47.6.1929-1935.2003&rft_id=info%3Apmid%2F12760869&rft.externalDocID=12760869
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon